34.30
-0.77(-2.20%)
Currency In USD
| Previous Close | 35.07 |
| Open | 35.44 |
| Day High | 35.44 |
| Day Low | 33.69 |
| 52-Week High | 44 |
| 52-Week Low | 14 |
| Volume | 17,684 |
| Average Volume | 18,468 |
| Market Cap | 89.77M |
| PE | -10.39 |
| EPS | -3.3 |
| Moving Average 50 Days | 35.32 |
| Moving Average 200 Days | 23.59 |
| Change | -0.77 |
If you invested $1000 in vTv Therapeutics Inc. (VTVT) 10 years ago, it would be worth $131.72 as of February 21, 2026 at a share price of $34.3. Whereas If you bought $1000 worth of vTv Therapeutics Inc. (VTVT) shares 5 years ago, it would be worth $328.54 as of February 21, 2026 at a share price of $34.3.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
vTv Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Feb 13, 2026 1:00 PM GMT
HIGH POINT, N.C., Feb. 13, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being
vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737
GlobeNewswire Inc.
Feb 02, 2026 1:00 PM GMT
Strategic amendment transforms regional partnership into global collaboration; Newsoara gains exclusive worldwide license to develop and commercialize novel PDE4 inhibitor vTv to receive $20 million upfront payment immediately upon execution of the a
vTv Therapeutics and M42’s IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health
GlobeNewswire Inc.
Dec 18, 2025 9:05 PM GMT
Trial to assess cadisegliatin as potential adjunctive therapy to insulin in patients with T2DHIGH POINT, N.C., Dec. 18, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced a Phase 2